Das Prostatakarzinom: Vergangenheit, Gegenwart, Zukunft

  • H. B. Carter
  • J. T. Isaacs


Das Prostatakarzinom ist die am häufigsten diagnostizierte maligne Erkrankung des Mannes über 65 [5]. Ferner steht es an zweiter Stelle der durch Tumoren verur-sachten Sterbefälle des Mannes [18]. Während der vergangenen 13 Jahre sind die alterskorrigierte Inzidenz und Mortalität des Prostatakarzinoms angestiegen [5, 18]. Aufgrund der Verschiebung in der Altersverteilung der Bevölkerung zugunsten derjenigen Altersgruppe, in der die meisten Prostatakarzinome auftreten, ist in Zukunft mit einer Zunahme der Anzahl von Prostatakarzinomen sowie der hierdurch verursachten Todesfälle zu rechnen.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M, Bignami P et al. (1986) Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1: 45–49PubMedGoogle Scholar
  2. 2.
    Carter HB, Coffey DS (1988) Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. J Urol 140: 173–175PubMedGoogle Scholar
  3. 3.
    Carter HB, Coffey DS (1988) Prostate cancer: The magnitude of the problem in the United States. In: Coffey DS, Resnick MI, Dorr FA, Karr JP (eds) A multidisciplinary analysis of controversies in the management of prostate cancer. Plenum Press, New York, pp 1–7CrossRefGoogle Scholar
  4. 4.
    Clark JR, Fallon BG, Frei E III (1987) Induction chemotherapy as initial treatment for advanced head and neck cancer: A model for the multidisciplinary treatment of solid tumors. In: DeVita JT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 175–195Google Scholar
  5. 5.
    Division of cancer prevention and control (1988) 1987 Annual cancer statistics review. National Cancer Institute, Bethesda/MD (NIH publication no. 88–2789 )Google Scholar
  6. 6.
    Dunn JE (1975) Cancer epidemiology in populations of the United States - with emphasis on Hawaii and California and Japan. Cancer Res 35: 3240 — 3245PubMedGoogle Scholar
  7. 7.
    Haenszel W, Kurihara M (1968) Studies of Japanese migrants: I. Mortality from cancer and other diseases among Japanese in the United States. Natl Cancer Inst 40: 43–68Google Scholar
  8. 8.
    Henry JM, Isaacs JT (1988) Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemothapy. J Urol 139: 1119–1123PubMedGoogle Scholar
  9. 9.
    Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5: 1–17PubMedCrossRefGoogle Scholar
  10. 10.
    Isaacs JT, Coffey DS (1981) Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070–5075PubMedGoogle Scholar
  11. 11.
    Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982) Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42: 2353–2361PubMedGoogle Scholar
  12. 12.
    Kyprianou N, Isaacs JT (1988) Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552–562PubMedCrossRefGoogle Scholar
  13. 13.
    Mohler JL, Partin AW, Coffey DS (1987) Prediction of metastatic potential by a new grading system of cell motility: Validation in the Dunning R-3327 prostatic adenocarcinoma model. J Urol 138: 168–170PubMedGoogle Scholar
  14. 14.
    Nowell PC (1986) Mechanisms of tumor progression. Cancer Res 46: 2203–2207PubMedGoogle Scholar
  15. 15.
    Ohno Y, Aoki K, Kuroishi T, Tominaga S (1984) Epidemiology of cancer of the urogenital organs in Japan. Rinsho Hinyokika 38: 555–569Google Scholar
  16. 16.
    Shackney SE, McCormack GW, Cuchural GJ (1978) Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 89: 107PubMedGoogle Scholar
  17. 17.
    Silverberg E (1987) Statistical and epidemiologic data on urologic cancer. Cancer 60: 692–717PubMedCrossRefGoogle Scholar
  18. 18.
    Silverberg E, Lubera JA (1988) Cancer statistics. CA 38: 14–15CrossRefGoogle Scholar
  19. 19.
    Smolev JK, Heston WDW, Scott WW, Coffey DS (1977) Characterization of the Dunning R3327H prostatic adenocarcinoma: An appropriate animal model for prostatic cancer. Cancer Treat Rep 61: 273–287PubMedGoogle Scholar
  20. 20.
    Stamey TA, McNeal JE, Freiha FS, Redwine E (1988) Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 139: 1235–1241PubMedGoogle Scholar
  21. 21.
    Sufrin G, Coffey DS (1975) Differences in the mechanism of action of medrogestone and cyproterone acetate. Invest Urol 13: 1–9PubMedGoogle Scholar
  22. 22.
    Tubiana M, Malaise EP (1976) Growth rate and cell kinetics in human tumors: Some prognostic and therapeutic implications. In: Symington T, Carter RL (eds) Scientific Foundations of Oncology. Year Book Medical Pubis, Chicago, p 126Google Scholar
  23. 23.
    Walsh PC, Jewett HJ (1980) Radical surgery for prostatic cancer. Cancer 45: 1906–1911PubMedGoogle Scholar
  24. 24.
    Wynder EL, Mabuchi K, Whitmore WF jr (1971) Epidemiology of cancer of the prostate. Cancer 28: 344–360PubMedCrossRefGoogle Scholar
  25. 25.
    Zincke H, Utz DC, Taylor WF (1986) Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: Role of adjuvant treatment for residual cancer and in disease progression. J Urol 135: 1199–1205PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • H. B. Carter
  • J. T. Isaacs
    • 1
  1. 1.Department of UrologyThe Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations